EUROPE SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

The Europe skin cancer diagnostics market growth assessment includes the analysis of Germany, Spain, France, Belgium, Poland, Italy, Nordic Countries, the United Kingdom, and Rest of Europe. In the United Kingdom, the increasing skin cancer incidence, the growing government funding, and the rising healthcare expenditure are estimated to propel the demand for the analyzed market. As per the NHS Foundation Trust, around 154,000 people are diagnosed with melanoma annually in the UK. Malignant melanoma has surged more than any other common cancer in Britain. Also, the number of people diagnosed with melanoma has increased by almost half in the last decade. Further, healthcare expenditure has gradually increased since 1997. Additionally, its share as part of the gross domestic product (GDP) has increased since 1990. 

In France, as per the 2020 World Health Organization (WHO) data, skin cancer deaths constituted 0.68% of total deaths. Also, the country is the second highest spender on healthcare in the European Union with regard to GDP percentage, spending 12.2% of its GDP on healthcare. In addition, it runs a statutory health insurance (SHI) system that provides universal coverage for its residents. Furthermore, France is moving toward a prevention, health promotion, and patient empowerment approach, breaking from a more paternalistic system. 

The Europe skin cancer diagnostics market segmentation includes screening type, gender, and type. The gender segment includes female and male. 

Men with white skin are evaluated to be at a higher risk of developing skin cancer. The rising vulnerability is accredited to occupational exposure to sunlight, potential delay in seeking medical attention for skin lesions, and outdoor activities. Also, there has been an increasing awareness among males regarding the importance of early detection and prevention of skin cancer. This has further led to increased demands for skin cancer diagnostic services and products customized for males. 

As per the American Academy of Dermatology Association, skin cancer rates are higher in males aged above 50. Besides, it is estimated that melanoma will affect 1 in 27 men in their lifetime. 

Whereas, for females, it is expected that melanoma will impact 1 in 40 women in their lifetime. Females are evaluated to project different patterns of skin cancer occurrence. This is attributed to factors like higher rates of indoor tanning, the use of hormonal contraceptives, and hormonal changes. However, women are often more proactive in seeking preventive measures and early detection of skin cancer through regular screenings and self-examinations. 

Some of the leading market players in the Europe skin cancer diagnostics market are NeraCare GmbH, Michelson Diagnostics Ltd, F Hoffmann-La Roche Ltd, etc.

F Hoffmann-La Roche Ltd is a biotechnology company that provides medicines for treating cancer, infectious diseases, respiratory diseases, central nervous system disorders, ophthalmological disorders, and other autoimmune diseases. It also offers tissue-based cancer diagnostics, diabetes management solutions, and in vitro diagnostics. The company offers its services and products to pharmacists, researchers, commercial laboratories, healthcare professionals, and hospitals. It is headquartered in Basel, Switzerland. 

One of its key products, cobas® 4800 BRAF V600 Mutation Test, is a real-time polymerase chain reaction (PCR) test for detecting and identifying BRAF V600 mutations in formalin-fixed paraffin-embedded tissue (FFPET) of human melanoma.